Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Verzenio

Roche Basel Switzerland

EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

Could face tough competition soon from a number of rivals

- PMLiVE

Pfizer’s Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund

Around 3,200 women in England could be eligible for treatment

- PMLiVE

FDA advisors say no to empagliflozin in type 1 diabetes

Approval of Boehringer, Lilly-partnered drug expansion looks unlikely

- PMLiVE

New hires at Amgen, Eli Lilly and Zosano

The latest movers in pharma

Eli Lilly HQ

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

Company still hopes drug can show promise in other cancer types

- PMLiVE

Eli Lilly shutters UK neuroscience unit, with 80 job losses expected

Company says decision is not related to Brexit

- PMLiVE

Novartis’ Cosentyx scores again in phase 3, strengthens approval claim

Scopes approval in non-radiographic axial spondyloarthritis

- PMLiVE

Novo follows Sanofi, Lilly with insulin price cut in US

Price cut will be effective from January 2020

- PMLiVE

FDA clears Lilly’s Taltz for ankylosing spondylitis

New indication boosts $1bn+ hopes for this year

- PMLiVE

Lilly psoriasis drug beats J&J’s Tremfya in head-to-head trial

Shifting expectations in psoriasis outcomes

- PMLiVE

Eli Lilly scores positive phase 3 results for Emgality in treatment resistant migraine

Hopes to catch up with rivals in the market

- PMLiVE

Lilly boosted by survival data for key growth drug Verzenio

Chases Pfizer's Ibrance

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links